Sandbox:Soroush: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 91: | Line 91: | ||
|1||2|||'''3''' | |1||2|||'''3''' | ||
|} | |} | ||
{{Family tree/start}} | |||
{{Family tree | | | | A01 |~|~|~| A02 | |A01= Soroush| A02= Soheil}} | |||
{{family tree | | | | |,|-| ^|- |.| | | | | | | | | | | | | | | | | |||
{{family tree | | |A |~|~|~|~|~|~|~|~|~|~|B| |A=Asghar|B=Akbar|}} | |||
{{Family tree/end}} | |||
Revision as of 20:14, 10 January 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]
Overview
Pathophysiology
Pathogenesis
- The pathogenesis of disease xyz is as follows:
- gsadjsdj
- ds,and,n
- ansdkfsk
ldsfjsjf
- dhs
| adksd | ||
|---|---|---|
| ,ks,KDSA | ||
antioxidants
- antioxidants dilemma [1]
| 0 | 1 | 2 | 3 |
|---|---|---|---|
| 1 | 2 | 3 | 4 |
| 0 |
| A1 | AA2 | !AAA3 |
|---|---|---|
| 1 | 2 | 3 |
| Avvvval | 1 | 2 | 3 |
|---|---|---|---|
| dovom | 1 | 2 | 3 |
jadval
| Avvvval | ||
|---|---|---|
| 1 | 2 | 3 |
| ! dovom | ||
| 1 | 2 | 3 |
{{family tree | | | | |,|-| ^|- |.| | | | | | | | | | | | | | | |
| Soroush | Soheil | ||||||||||||||||||||||||||||||||||||||
| Asghar | Akbar | ||||||||||||||||||||||||||||||||||||||
Soroush Seifirad CV
Address
- 930 commmonwealth
- Baim institute
- clinical research
- Baim institute
- Education
- NODET
- TUMS
- TBZMD
Published articles
- Pirfenidone
- Pirfenidone
- pirfenidone
Clinical trials
- RCTs
"hello"
- how are you? aaa bbb
- I am fine thank you
"I think I have to make a table now and insert some pictures"
conference
- Spain
- Netherlands
References
- ↑ Seifirad S, Ghaffari A, Amoli MM (2014). "The antioxidants dilemma: are they potentially immunosuppressants and carcinogens?". Front Physiol. 5: 245. doi:10.3389/fphys.2014.00245. PMC 4094884. PMID 25071590 PMID: 25071590 Check
|pmid=value (help).